Merck & Co., Inc. (NYSE: MRK), one of the world’s largest pharmaceutical companies, was founded in 1891 and is headquartered in Rahway, New Jersey. Today, Merck CEO Robert M. Davis leads the company’s $65 billion business and a global workforce of approximately 69,000 employees. Appointed CEO on July 1, 2021, succeeding the legendary Kenneth Frazier, Davis was elevated to Chairman of the Board in December 2022. A finance executive by training with a J.D. and MBA from Northwestern University, Davis is now navigating one of pharma’s greatest challenges: preparing Merck’s pipeline to replace Keytruda, the world’s best-selling drug generating over $31 billion annually, as it faces patent expiration around 2028.

(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Robert M. Davis – Quick Facts

Merck Competitors

Merck & Co. operates in the highly competitive global pharmaceutical industry. The key competitors of Merck include:

• Eli Lilly and Company – leader in diabetes and obesity drugs (Mounjaro, Zepbound)
• Johnson & Johnson – diversified pharma, medtech, and consumer health
• AbbVie – immunology leader (Humira, Skyrizi, Rinvoq)
• Pfizer – oncology, vaccines, and rare diseases
• Roche – oncology and diagnostics leader
• AstraZeneca – fast-growing oncology pipeline
• Novartis – innovative medicines and generics
• Bristol-Myers Squibb – oncology and cardiovascular focus (Opdivo)

Robert Davis Net Worth 2026 – Merck CEO Salary

As of 2026, Robert Davis net worth is estimated at approximately $55–83 million USD, based on his disclosed Merck stock holdings and SEC filings. Davis directly owns approximately 443,602 shares of Merck & Co. (MRK) stock, valued at over $52 million based on recent share prices. He also retains approximately 120,442 shares of Baxter International (BAX) stock worth over $3 million from his prior career.

Merck CEO Compensation Breakdown (FY2024)

Merck Net Worth 2026 – Is Merck Profitable?

Yes, Merck is a highly profitable company. Under CEO Robert Davis, Merck reported full-year 2025 worldwide sales of $65.0 billion, driven by its blockbuster oncology drug Keytruda and growing contributions from newer products like Winrevair and Capvaxive. Merck has set 2026 revenue guidance of $65.5–$67.0 billion.

Merck Financial Summary (FY2024 vs. FY2025)

(Recommended: Eli Lilly CEO Email & Net Worth – David Ricks Salary)

Merck CEO Email Address | Robert Davis Contact

Below are the official contact details and social media profiles for Merck CEO Robert M. Davis:

Career & Education – Company, University, & College

Robert M. Davis’s career spans over three decades in corporate finance and healthcare, rising through progressively senior roles at Eli Lilly, Baxter International, and Merck. Below is his complete career timeline:

Robert Davis Career Timeline

Before becoming Merck CEO, Robert Davis built a distinguished career across corporate finance and healthcare leadership. He spent 14 years at Eli Lilly and Company in various finance roles of increasing responsibility, including Director of Corporate Financial Planning.

In 2004, Davis joined Baxter International, where he served as Treasurer (2004–2006), Corporate Vice President and Chief Financial Officer (2006–2010), and then Corporate Vice President and President of the Medical Products business (2010–2014). His decade at Baxter gave him both financial and operational leadership experience across a major healthcare company.

Davis joined Merck as Executive Vice President and CFO in 2014. His role was expanded in 2016 to include responsibility for IT, procurement, corporate strategy, and business development under the umbrella of Global Services. He was named President in April 2021 and became CEO on July 1, 2021, succeeding Kenneth Frazier, one of the most respected CEOs in American business. He was unanimously elected Chairman of the Board effective December 1, 2022.

(Related: AstraZeneca CEO Email & Net Worth – Pascal Soriot Salary)

Education

Davis’s combination of a law degree and MBA from Northwestern, paired with a finance undergraduate degree, is unusual for a pharmaceutical CEO. This dual background in law and business reflects his career path through corporate finance, strategy, and deal-making rather than the scientific or medical track more common among pharma leaders.

Robert Davis Wiki – Age, Family, & More

Merck CEO Robert M. Davis (age 58) is based in the New Jersey area near Merck’s headquarters in Rahway. Born circa 1967, Davis keeps his personal and family life private, and specific details about his spouse and children are not widely disclosed. He has publicly mentioned that family members have been affected by cancer, which gives deep personal meaning to his leadership of a company whose flagship product, Keytruda, is the world’s leading cancer immunotherapy.

Davis holds three degrees — a B.S. in Finance, a Juris Doctor, and an MBA — making him one of the most academically credentialed CEOs in the pharmaceutical industry. His unique law-and-finance background set him apart from the typical science-trained pharma executive.

Board Positions & External Roles

• PhRMA – Chairman of the Board of Directors (Pharmaceutical Research and Manufacturers of America)
• IFPMA – Vice President (International Federation of Pharmaceutical Manufacturers and Associations)
• Duke Energy Corporation – Board of Directors; Chair of Finance and Risk Management Committee
• Northwestern Law Board – Member of the Northwestern Law Board at Northwestern Pritzker School of Law
• Catalyst – Board member (global nonprofit promoting workplace equity for women)
• Project HOPE – Board member (global health nonprofit empowering healthcare workers)

Notable Achievements Under Davis’s Leadership

• Keytruda QLEX FDA Approval (Sep 2025) – Secured approval of subcutaneous Keytruda formulation, extending patent protection through 2041
• $20B+ in Acquisitions (2025) – Led major deals for Verona Pharma (~$10B) and Cidara Therapeutics (~$10B)
• Winrevair Launch Success – Grew PAH drug from launch to $1.4B in annual sales within first full year
• CEO Today Top 50 – Recognized as one of the top 50 CEOs globally
• $3B Cost-Cutting Initiative – Announced restructuring program to prepare for Keytruda patent cliff
• Oncology Business Split – Reorganized Merck’s oncology into a standalone business unit for strategic focus

About Merck & Co.

Merck & Co., Inc. (known as MSD outside the United States and Canada) is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891, it is one of the largest pharmaceutical companies in the world. Key products and therapeutic areas include:

Merck trades on the New York Stock Exchange under the ticker symbol MRK with a market capitalization of approximately $300 billion as of March 2026. The company employs approximately 69,000 people worldwide. Merck set 2026 revenue guidance of $65.5–$67.0 billion, with CEO Davis targeting $70B+ in annual revenue by the mid-2030s from its 20+ growth drivers.

Frequently Asked Questions (FAQ)

Who is the current CEO of Merck?

Robert M. Davis is the Chairman, CEO, and President of Merck & Co., Inc. He became CEO on July 1, 2021, succeeding Kenneth Frazier, and was named Chairman of the Board in December 2022.

What is Robert Davis’s net worth in 2026?

As of 2026, Robert Davis’s net worth is estimated at $55–83 million, primarily based on his disclosed Merck stock holdings of approximately 443,602 shares valued at over $52 million, plus additional Baxter International shares.

What is Merck CEO’s salary?

Robert Davis’s total compensation for fiscal year 2024 was approximately $23.2 million, including a $1.62 million base salary, $2.76 million bonus, $4.65 million in stock options, and $13.1 million in stock awards. Over 93% of his compensation is performance-based.

What is Merck CEO’s email address?

Merck CEO Robert Davis can be contacted via [email protected]. He is also active on LinkedIn. For corporate inquiries, contact Merck headquarters at (908) 740-4000.

What did Robert Davis do before Merck?

Before becoming Merck CEO, Robert Davis spent 14 years at Eli Lilly in various finance roles, then a decade at Baxter International where he served as CFO and President of the Medical Products division. He joined Merck as CFO in 2014.

What is Keytruda and why is it important to Merck?

Keytruda (pembrolizumab) is Merck’s blockbuster cancer immunotherapy drug and the world’s best-selling drug, generating $31.7 billion in FY2025. It accounts for nearly half of Merck’s total revenue. Merck received FDA approval for a subcutaneous version (Keytruda QLEX) in September 2025, extending patent protection through 2041.

Article last updated:February 2026March 4, 2026